New York, NY – A promising new long-acting therapy has emerged as a potential rival to the widely used Eylea in the treatment of eye diseases. EyePoint Pharmaceuticals, a company known for its Durasert technology, has been gaining attention in the market. In a recent development, the company’s lead drug candidate, EYP-1901, now known as Duravyu, has shown positive results in its Phase 2 Davio study.

The advantage of EyePoint’s product lies in its proprietary delivery system, which allows for once-every-six-month dosing frequency. This is a significant improvement compared to current standards of care in Wet AMD, such as Eylea from Regeneron, which requires more frequent dosing. EyePoint’s success in demonstrating statistical non-inferiority in its Phase 2 study has boosted its chances of winning approval for Duravyu.

Following the positive news, EyePoint’s share price saw a significant surge, reflecting investors’ optimism in the company’s future prospects. However, there are some concerns that investors should be aware of, such as potential competition from rival pharmaceutical companies and the need for strong marketing strategies to compete effectively in the market.

Despite the initial success, EyePoint faced a setback in its Phase 2 Pavia study for non-proliferative diabetic retinopathy (NPDR), where the trial did not meet the pre-specified primary endpoint. This raised questions about the reliability of the company’s data and the potential challenges it may face in the future.

Looking ahead, EyePoint is moving forward with its Phase 3 pivotal study of Duravyu in Wet AMD, with first patient dosing expected in 2024. The company is also exploring the potential of Duravyu in diabetic macular edema as a maintenance treatment. As the company continues to progress with its clinical trials, investors are closely watching for any new developments that may impact the future prospects of EyePoint Pharmaceuticals.